Is GSK’s Exit and IDE034’s FDA Green Light Reframing the Investment Case For IDEAYA Biosciences (IDYA)?

Simply Wall St.12-09

In early December 2025, GSK notified IDEAYA Biosciences that it will terminate their 2020 collaboration, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, while IDEAYA also ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590315296?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-09 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590315296","market":"nz","top_or_hot":-1,"title":"Is GSK’s Exit and IDE034’s FDA Green Light Reframing the Investment Case For IDEAYA Biosciences (IDYA)?","media":"Simply Wall St.","content":"<div>\n<p>In early December 2025, GSK notified IDEAYA Biosciences that it will terminate their 2020 collaboration, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, while IDEAYA also ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-gsks-exit-and-ide034s-fda-green-light-reframing-the-inves\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is GSK’s Exit and IDE034’s FDA Green Light Reframing the Investment Case For IDEAYA Biosciences (IDYA)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs GSK’s Exit and IDE034’s FDA Green Light Reframing the Investment Case For IDEAYA Biosciences (IDYA)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-09 11:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-gsks-exit-and-ide034s-fda-green-light-reframing-the-inves><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early December 2025, GSK notified IDEAYA Biosciences that it will terminate their 2020 collaboration, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, while IDEAYA also ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-gsks-exit-and-ide034s-fda-green-light-reframing-the-inves\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-gsks-exit-and-ide034s-fda-green-light-reframing-the-inves","article_id":"2590315296","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-idya/ideaya-biosciences/news/is-gsks-exit-and-ide034s-fda-green-light-reframing-the-inves","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590315296","pubTimestamp":1765250157,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early December 2025, GSK notified IDEAYA Biosciences that it will terminate their 2020 collaboration, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, while IDEAYA also secured FDA clearance to begin a Phase 1 trial of its bispecific B7H3/PTK7 ADC IDE034 for multiple solid tumors in 2026.\nThis combination of a major partnership unwind and the advancement of a potentially first-in-class oncology asset highlights IDEAYA’s increasing control over its pipeline and its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","BK4139":"生物科技","IDYA":"IDEAYA Biosciences","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","GSK":"葛兰素史克","BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"GSK的退出和IDE034的FDA批准是否正在重新构建IDEAYA Biosciences(IDYA)的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDYA":1.5,"GSK.UK":0.6,"GSK":1.5},"content_text":"In early December 2025, GSK notified IDEAYA Biosciences that it will terminate their 2020 collaboration, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) programs, while IDEAYA also secured FDA clearance to begin a Phase 1 trial of its bispecific B7H3/PTK7 ADC IDE034 for multiple solid tumors in 2026. This combination of a major partnership unwind and the advancement of a potentially first-in-class oncology asset highlights IDEAYA’s increasing control over its pipeline and its confidence in funding operations into 2030. We’ll now examine how gaining full ownership of key DNA repair programs while advancing IDE034 into the clinic shapes IDEAYA’s investment narrative. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.AdvertisementWhat Is IDEAYA Biosciences' Investment Narrative?To own IDEAYA Biosciences, you have to be comfortable backing an R&D-heavy, loss-making oncology company whose value is tied to clinical execution rather than current earnings. The stock has already outperformed the broader market, and the key near term catalysts still sit with darovasertib data and any clarity on potential regulatory paths in uveal melanoma, plus updates across the IDE397 and IDE161 DNA repair programs. The GSK exit changes the story at the margin: it hands IDEAYA full control of IDE275 and IDE705, but removes a large pharma partner and pushes decisions on spend and partnering squarely back onto management. By contrast, IND clearance for IDE034 adds another early clinical shot on goal without altering the core risk that IDEAYA remains unprofitable and reliant on capital markets. However, one issue around IDEAYA’s spending and partnership decisions is easy to miss, yet material for shareholders.\n\nOur valuation report unveils the possibility IDEAYA Biosciences' shares may be trading at a premium.Exploring Other PerspectivesIDYA 1-Year Stock Price Chart Two Simply Wall St Community fair value views span from US$49.47 to a very large upper estimate, underscoring how far apart individual expectations can be. Against that backdrop, the GSK collaboration unwind and IDE034’s entry into the clinic leave investors weighing pipeline breadth against persistent losses and a rich sales multiple.Explore 2 other fair value estimates on IDEAYA Biosciences - why the stock might be worth just $49.47!Build Your Own IDEAYA Biosciences NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your IDEAYA Biosciences research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.Want Some Alternatives?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.The latest GPUs need a type of rare earth metal called Terbium and there are only 36 companies in the world exploring or producing it. Find the list for free.Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590315296","isCrawlerRequest":true}